Hostname: page-component-848d4c4894-xfwgj Total loading time: 0 Render date: 2024-06-17T17:28:33.487Z Has data issue: false hasContentIssue false
  • English
  • Français

Basic science (January 2007)

Published online by Cambridge University Press:  13 June 2007

R. Sutherland  and
J. Scorer
R. Sutherland
Affiliation:
Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
J. Scorer
Affiliation:
Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Journals Watch
Information
Breast Cancer Online , Volume 10 , Issue 5 , May 2007 , pp. 1 - 3 , e10
Copyright
© 2007 Cambridge University Press

References

Belous AR, Hachey DL, Dawling S, Roodi N, Parl FF. Cytochrome P4501B1-mediated estrogen metabolism results in estrogen-deoxyribonucleoside adduct formation. Cancer Res 2007; 67: 812–817.Google Scholar
Bhati R, Gokmen-Polar Y, Sledge GW, Fan C, Nakshatri H, Ketelsen D, Borchers CH, Dial MJ, Patterson C, Klauber-DeMore N. 2-methoxyestradiol inhibits the anaphase-promoting complex and protein translation in human breast cancer cells. Cancer Res 2007; 67: 702–708.Google Scholar
Bosco EE, Wang Y, Xu H, Zilfou JT, Knudsen KE, Aronow BJ, Lowe SW, Knudsen ES. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest 2007; 117: 218–228.Google Scholar
Buchholz S, Schally AV, Engel JB, Hohla F, Heinrich E, Koester F, Varga JL, Halmos G. Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel. Proc Natl Acad Sci USA 2007; 104 (6): 1943–1946.Google Scholar
Chang MY, Boulden J, Sutanto-Ward E, Duhadaway JB, Soler AP, Muller AJ, Prendergast GC. Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression. Cancer Res 2007; 67: 100–107.Google Scholar
Climent J, Dimitrow P, Fridlyand J, Palacios J, Siebert R, Albertson DG, Gray JW, Pinkel D, Lluch A, Martinez-Climent JA. Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer. Cancer Res 2007; 67: 818–826.Google Scholar
Donato LJ, Suh JH, Noy N. Suppression of mammary carcinoma cell growth by retinoic acid: the cell cycle control gene Btg2 is a direct target for retinoic acid receptor signaling. Cancer Res 2007; 67: 609–615.Google Scholar
Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, Blobe GC. The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest 2007; 117: 206–217.Google Scholar
Esslimani-Sahla M, Thezenas S, Simony-Lafontaine J, Kramar A, Lavaill R, Chalbos D, Rochefort H. Increased expression of fatty acid synthase and progesterone receptor in early steps of human mammary carcinogenesis. Int J Cancer 2007; 120: 224–229.Google Scholar
Faivre EJ, Lange CA. Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. Mol Cell Biol 2007; 27: 466–480.Google Scholar
Gestl SA, Leonard TL, Biddle JL, Debies MT, Gunther EJ. Dormant Wnt-initiated mammary cancer can participate in reconstituting functional mammary glands. Mol Cell Biol 2007; 27: 195–207.Google Scholar
Iliopoulos D, Fabbri M, Druck T, Qin HYR, Han SY, Huebner K. Inhibition of breast cancer cell growth in vitro and in vivo: effect of restoration of Wwox expression. Clin Cancer Res 2007; 13: 268–274.Google Scholar
Julien SG, Dube N, Read M, Penney J, Paquet M, Han Y, Kennedy BP, Muller WJ, Tremblay ML. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. Nat Genet 2007; 39: 338–346.Google Scholar
Korah R, Das K, Lindy ME, Hameed M, Wieder R. Coordinate loss of fibroblast growth factor 2 and laminin 5 expression during neoplastic progression of mammary duct epithelium. Hum Pathol 2007; 38: 154–160.Google Scholar
Kotsopoulos J, Chen Z, Vallis KA, Poll A, Ainsworth P, Narod SA. DNA repair capacity as a possible biomarker of breast cancer risk in female BRCA1 mutation carriers. Br J Cancer 2007; 96: 118–125.Google Scholar
Labbe E, Lock L, Letamendia A, Gorska AE, Gryfe R, Gallinger S, Moses HL, Attisano L. Transcriptional cooperation between the transforming growth factor-beta and wnt pathways in mammary and intestinal tumorigenesis. Cancer Res 2007; 67: 75–84.Google Scholar
Lahmann PH, Friedenreich C, Schuit AJ, Salvini S, Allen NE, Key TJ, Khaw KT, Bingham S, Peeters PHM, Monninkhof E, Bueno-De-Mesquita HB, Wirfaelt E, Manjer J, Gonzales CA, Ardanaz E, Amiano P, Quiros JR, Navarro C, Martinez C, Berrino F, Palli D, Tumino R, Panico S, Vineis P, Trichopoulou A, Bamia C, Trichopoulos D, Boeing H, Schulz M, Linseisen J, Chang-Claude J, Chapelon FC, Fournier A, Boutron-Ruault MC, Tjonneland A, Johnson NF, Overvad K, Kaaks R, Riboli E. Physical activity and breast cancer risk: the European prospective investigation into cancer and nutrition. Cancer Epidemiol BiomarkPrevent 2007; 16: 36–42.Google Scholar
Lee YK, Thomas SN, Yang AJ, Ann DK. Doxorubicin down-regulates Kruppel-associated box domain-associated protein 1 sumoylation that relieves its transcription repression on p21(WAF1/CIP1) in breast cancer MCF-7 cells. J Biol Chem 2007; 282: 1595–1606.Google Scholar
Lei HX, Hemminki K, Johansson R, Enquist K, Henriksson R, Lenner P, Forsti A. Single nucleotide polymorphisms in the DMBT1 promoter and the progression of breast cancer. Int J Cancer 2007; 120: 447–449.Google Scholar
Letessier A, Garrido-Urbani S, Ginestier C, Fournier G, Esterni B, Monville F, Adelaide J, Geneix J, Xerri L, Dubreuil P, Viens P, Charafe-Jauffret E, Jacquemier J, Birnbaum D, Lopez M, Chaffanet M. Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer. Oncogene 2007; 26: 298–307.Google Scholar
Li H, Cherukuri P, Li N, Cowling V, Spinella M, Cole M, Godwin AK, Wells W, DiRenzo J. Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. Cancer Res 2007; 67: 501–510.Google Scholar
Maroulakou IG, Oemler W, Naber SP, Tsichlis PN. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/Neu and MMTV-polyoma middle T transgenic mice. Cancer Res 2007; 67: 167–177.Google Scholar
Park BK, Zhang HL, Zeng QH, Dai JL, Keller ET, Giordano T, Gu KN, Shah V, Pei L, Zarbo RJ, McCauley L, Shi ST, Chen SQ, Wang CY. NF-kappa B in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 2007; 13: 62–69.Google Scholar
Pervin S, Singh R, Hernandez E, Wu GY, Chaudhuri G. Nitric oxide in physiologic concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: involvement of mammalian target of Rapamycin/eIF4E pathway. Cancer Res 2007; 67: 289–299.Google Scholar
Rakha EA, El-Sayed ME, Green AR, Lee AHS, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109: 25–32.Google Scholar
Rojo F, Najera L, Lirola J, Jimenez J, Guzman M, Sabadell MD, Baselga J, Cajal SRY. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res 2007; 13: 81–89.Google Scholar
Savage K, Lambros MBK, Robertson D, Jones RL, Jones C, Mackay A, James M, Hornick JL, Pereira EM, Milanezi F, Fletcher CDM, Schmitt FC, Ashworth A, Reis JS. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res 2007; 13: 90–101.Google Scholar
Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 2007; 282: 1479–1486.Google Scholar
Singh VK, Zhou Y, Marsh JA, Uversky VN, Forman-Kay JD, Liu JW, Jia ZC. Synuclein-gamma targeting peptide inhibitor that enhances sensitivity of breast cancer cells to antimicrotubule drugs. Cancer Res 2007; 67: 626–633.Google Scholar
Sleeman KE, Kendrick H, Robertson D, Isacke CM, Ashworth A, Smalley MJ. Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland. J Cell Biol 2007; 176: 19–26.Google Scholar
Takabatake D, Fujita T, Shien T, Kawasaki K, Taira N, Yoshitomi S, Takahashi H, Ishibe Y, Ogasawara Y, Doihara H. Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCMADR, MDA-MB-231). Int J Cancer 2007; 120: 181–188.Google Scholar
Tang SS, Zhang Z, Tan SL, Tang MHE, Kumar AP, Ramadoss SK, Bajic VB. KBERG: Knowledge Base for Estrogen Responsive Genes. Nucleic Acids Res 2007; 35: D732–D736.Google Scholar
Vachon CM, Brandt KR, Ghosh K, Scott CG, Maloney SD, Carston MJ, Pankratz VS, Sellers TA. Marnmographic breast density as a general marker of breast cancer risk. Cancer Epidemiol BiomarkPrevent 2007; 16: 43–49.Google Scholar
Vegran F, Boidot R, Oudin C, Defrain C, Rebucci M, Lizard-Nacol S. Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer. Oncogene 2007; 26: 290–297.Google Scholar
Wang Y, He QY, Chen HM, Chiu JF. Synergistic effects of retinoic acid and tamoxifen on human breast cancer cells: proteomic characterization. Exp Cell Res 2007; 313: 357–368.Google Scholar
Weischer M, Bojesen SE, Tybjaerg-Hansen A, Axelsson CK, Nordestgaard BG. Increased risk of breast cancer associated with CHEK2*1100delC. J Clin Oncol 2007; 25: 57–63.Google Scholar
Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, de Vijver MV, Wheeler TM, Hayes DF. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118–145.Google Scholar
Wood CE, Register TC, Lees CJ, Chen HY, Kimrey S, Cline JM. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat 2007; 101: 125–134.Google Scholar
Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM. WNT/β-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA 2007; 104: 618–623Google Scholar
Yao ES, Zhang H, Chen YY, Lee B, Chew K, Moore D, Park C. Increased beta(1) integrin is associated with decreased survival in invasive breast cancer. Cancer Res 2007; 67: 659–664.Google Scholar
Zhang H, Pelzer AM, Kiang DT, Yee D. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res 2007; 67: 391–397.Google Scholar
Zhang JP, Warren MA, Shoemaker SF, Ip MM. NF kappa B1/p50 is not required for tumor necrosis factor-stimulated growth of primary mammary epithelial cells: implications for NF kappa B2/p52 and RelB. Endocrinology 2007; 148: 268–278.Google Scholar
Zhu QW, Krakowski AR, Dunham EE, Wang L, Bandyopadhyay A, Berdeaux R, Martin GS, Sun LZ, Luo KX. Dual role of SnoN in mammalian tumorigenesis. Mol Cell Biol 2007; 27: 324–339.Google Scholar